Several innovative cancer therapies and strategic partnerships emerged as focal developments. Roche reported promising Phase 3 trial results combining bispecific and antibody-drug conjugate therapies for large B-cell lymphoma, significantly reducing progression risk. Meanwhile, Harbour Biomed licensed its bispecific T-cell engager to Otsuka Pharmaceutical for up to $670 million, targeting autoimmune diseases. Also, Leap Therapeutics announced major workforce reductions and clinical trial cessation while assessing strategic alternatives, citing trial data for its anti-DKK1 antibody.